ICM
FBLG icon

Islay Capital Management’s FibroBiologics FBLG Stock Holding History

Islay Capital Management’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$223 Sell
169
-1
-0.6% -$6 ﹤0.01% 197
2025
Q4 		$763 Hold
170
– – ﹤0.01% 201
2025
Q3 		$1.85K Buy
170
+147
+639% +$1.76K ﹤0.01% 192
2025
Q2 		$280 Buy
+23
New +$415 ﹤0.01% 198

Other funds holding FBLG

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FEG
Fund Evaluation Group Cincinnati, Ohio $3.25B AUM 14.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM

Islay Capital Management's FBLG Position: Q1 2026 in Review

Islay Capital Management reduced its FibroBiologics (FBLG) stake by 0.59% in Q1 2026, selling an estimated $6 and leaving 169 shares worth $223. The position accounts for ﹤0.01% of the portfolio, ranked #197.

Islay Capital Management first reported a position in FBLG in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.85K in Q3 2025. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

  • Islay Capital Management held 169 shares of FibroBiologics worth $223 as of Q1 2026.
  • Islay Capital Management sold 1 FibroBiologics share in Q1 2026, an estimated $6.
  • FibroBiologics made up ﹤0.01% of Islay Capital Management's portfolio in Q1 2026, its #197 holding.
  • Islay Capital Management first reported a position in FibroBiologics in Q2 2025 and has held it in 4 quarters since.
  • Islay Capital Management's FibroBiologics position peaked at $1.85K in Q3 2025.
  • 17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Islay Capital Management's 13F filing for Q1 2026, filed 14 May 2026.